The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder
Abstract
OBJECTIVE: This study examined whether d-cycloserine, a partial agonist at the N-methyl-D-aspartate (NMDA) glutamatergic receptor, enhances the efficacy of behavior therapy for obsessive-compulsive disorder (OCD). METHOD: A randomized, double-blind, placebo-controlled trial investigating D-cycloserine versus placebo augmentation of behavior therapy was conducted in 23 OCD patients. Patients first underwent a diagnostic interview and pretreatment evaluation, followed by a psychoeducational/treatment planning session. Then they received 10 behavior therapy sessions. Treatment sessions were conducted twice per week. One hour before each of the behavior therapy sessions, the participants received either D-cycloserine, 100 mg, or a placebo. RESULTS: Relative to the placebo group, the D-cycloserine group's OCD symptoms were significantly more improved at mid-treatment, and the D-cycloserine group's depressive symptoms were significantly more improved at posttreatment. CONCLUSIONS: These data provide support for the use of D-cycloserine as an augmentation of behavior therapy for OCD and extend findings in animals and other human disorders suggesting that behavior therapy acts by way of long-term potentiation of glutamatergic pathways and that the effects of behavior therapy are potentiated by an NMDA agonist.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“research demonstrated that, relative to those given a placebo pill, patients taking d-cycloserine before engaging in exposure therapy experienced a faster rate of symptom improvement in the first few weeks of receiving ERP.[57]”
From Exposure and response prevention for obsessive-compulsive disorder: A review and new directions (2019) · cites this paper as [57]
In the citing paper
“The findings of the present study suggest that the weak or null effects observed in these previous studies may be accounted for by large individual variability in fear extinction observed in therapy sessions.”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [14]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Structured Clinical Interview for DSM-IV Axis I Disorders
Spitzer, R. L., First, M. B., & Gibbon, M. (1997) · Medical Entomology and Zoology · Cited by 3,582
Fear conditioning induces associative long-term potentiation in the amygdala
Rogan, M. T., Stäubli, U. V., & LeDoux, J. E. (1997) · Nature · doi:10.1038/37601 · Cited by 1,310
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Why We Think Plasticity Underlying Pavlovian Fear Conditioning Occurs in the Basolateral Amygdala
Fanselow, M. S., & LeDoux, J. E. (1999) · Neuron · doi:10.1016/s0896-6273(00)80775-8 · Cited by 933
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 4×
“on social anxiety (14), in our OCD study, the medication was given 1 hour before each session.”
BackgroundMethodInfluentialWhittal, M. L., Thordarson, D. S., & McLean, P. D. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.11.012 · Cited by 417
Effects of D-cycloserine on extinction of conditioned freezing.
Ledgerwood, L., Richardson, R., & Cranney, J. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.2.341 · Cited by 388
D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder
Kushner, M. G., Kim, S. W., Donahue, C. B., THURAS, P. D., Adson, D. E., Kotlyar, M., McCabe, J., Peterson, J., & Foa, E. B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.020 · Cited by 384
Foa, E. B., Franklin, M. E., & Moser, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01552-4 · Cited by 219
Royer, S., & Paré, D. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00455-4 · Cited by 210
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.005 · Cited by 209
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8480 · Cited by 200
Davis, M., & Myers, K. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01507-x · Cited by 200
Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90687-4 · Cited by 190
The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning.
Baker, J. D., & Azorlosa, J. L. (1996) · Behavioral Neuroscience · doi:10.1037//0735-7044.110.3.618 · Cited by 179
The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning.
Baker, J. D., & Azorlosa, J. L. (1996) · Behavioral Neuroscience · doi:10.1037/0735-7044.110.3.618 · Cited by 179
Post-treatment effects of exposure therapy and clomipramine in obsessive–compulsive disorder
Simpson, H. B., Liebowitz, M. R., Foa, E. B., Kozak, M. J., Schmidt, A. B., Rowan, V., Petkova, E., Kjernisted, K., Huppert, J. D., Franklin, M. E., et al. (2004) · Depression and Anxiety · doi:10.1002/da.20003 · Cited by 161
Davis, M. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02138.x · Cited by 154
Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats
Parnas, A. S., Weber, M. F., & Richardson, R. (2005) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2005.01.001 · Cited by 146
GOFF, D. C., Herz, L. R., Posever, T. A., Shih, V. E., Tsai, G. E., Henderson, D. C., Freudenreich, O., Evins, A. E., Yovel, I., Zhang, H., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2032-2 · Cited by 116
Goosens, K. A., & Maren, S. (2002) · Hippocampus · doi:10.1002/hipo.10099 · Cited by 112
Effects of d-cycloserine on negative symptoms in schizophrenia
Duncan, E., Szilagyi, S., Schwartz, M. P., Bugarski‐Kirola, D., Kunzova, A., Negi, S., Stephanides, M., Efferen, T. R., Angrist, B., Peselow, E. D., et al. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.013 · Cited by 90
Cox, J., & Westbrook, R. F. (1994) · PubMed · Cited by 74
D-cycloserine for Alzheimer's disease
Jones, R. W., Laake, K., & Øksengård, A. R. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003153 · Cited by 72
Boje, K. M., Wong, G., & Skolnick, P. (1993) · Brain Research · doi:10.1016/0006-8993(93)91239-o · Cited by 69
Evaluation of Cycloserine in the Treatment of Alzheimer's Disease
Fakouhi, T. D., Jhee, S. S., Sramek, J. J., Benes, C. O., Schwartz, P., Hantsburger, G., Herting, R. L., Swabb, E. A., & Cutler, N. R. (1995) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879500800405 · Cited by 51
D-cycloserine Inhibits Amygdala Responses During Repeated Presentations of Faces
Britton, J. C., Gold, A. L., Feczko, E., Rauch, S. L., Williams, D., & Wright, C. I. (2007) · CNS Spectrums · doi:10.1017/s1092852900021398 · Cited by 16
Self-citation
Research works printed but not linked: 4
- Cox J, 1994, Q J Exp Psychol B, 47, 187
- Kozak MJ, 1997, Tex
- First MB, 1995, Patient Edition (SCIDP, version 2.0).
- Beck AT, 1996, Steer RA
Cited by
Sorted by citations
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective
Grupe, D. W., & Nitschke, J. B. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3524 · Cited by 2,007
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adding d-cycloserine may hasten the onset of improvements with ERP, with significant benefits over placebo during the first four or five ERP sessions [698-700], but this effect has not been seen in all studies [701].”
BackgroundPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Metadata
- Authors
- Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L.
- Affiliations
- Harvard University (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2008-03
- Volume
- 165
- Issue
- 3
- Pages
- 335-341
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2038335379
- Semantic Scholar
- d1309dc52689e30eae911778d6e9c8b6cc61a87f
- Cited by
- 358
- References
- 30
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 11 · 2018: 16 · 2017: 24 · 2016: 13 · 2015: 24 · 2014: 36 · 2013: 33 · 2012: 41
- FWCI
- 48.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- D-cycloserine, obsessive-compulsive disorder, behavior therapy, augmentation therapy, NMDA receptor partial agonist, glutamatergic pathways, long-term potentiation, depressive symptoms
- MeSH terms
- Adult, Animals, Behavior Therapy, Combined Modality Therapy, Cycloserine, Double-Blind Method, Female, Follow-Up Studies, Humans, Implosive Therapy, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Rats, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
